BRIEF-Merck says FDA grants breakthrough therapy designation to Keytruda

* FDA accepts supplemental biologics license application,

assigns priority review and grants breakthrough therapy

designation to Merck's Keytruda (pembrolizumab) for first-line

treatment of patients...

Read more